Katie Peng has more than 30 years of experience in the pharma/biotech industry managing extensive product portfolios in both the US and global markets. Since 2021, Katie has been the Chief Commercial Officer for Denali Therapeutics. She is responsible for commercializing Denali’s pipeline and for establishing a global organization to serve patients. She is a member of the executive management team and has a leadership role in shaping company strategy, culture, and vision. Katie also serves as a board member for California Life Sciences and Adicet Bio.
Prior to joining Denali, Katie was the Senior Vice President, Business Unit Head at Genentech. She was responsible for the neurology, ophthalmology, immunology, respiratory, and rare diseases portfolio. She spent almost two decades at Genentech and Roche, holding several senior leadership positions. During her tenure, Katie successfully launched multiple products in neurology, oncology, and rare diseases. Between 2012-2017, she was a General Manager for Roche in two APAC countries. Katie has broad US and global experience that spans marketing, sales, market access, medical affairs, and business planning.
Katie began her career as a research scientist at Allergan. After earning her MBA, she joined Amgen where she held several commercial roles. Katie holds a BA from the University of California, Berkeley and an MBA from the Kelley School of Business, Indiana University.
What is Katie Peng's net worth?
The estimated net worth of Katie Peng is at least $1.53 million as of September 16th, 2025. Ms. Peng owns 33,914 shares of Scholar Rock stock worth more than $1,532,913 as of December 4th. This net worth estimate does not reflect any other investments that Ms. Peng may own. Learn More about Katie Peng's net worth.
How do I contact Katie Peng?
Has Katie Peng been buying or selling shares of Scholar Rock?
Katie Peng has not been actively trading shares of Scholar Rock during the past quarter. Most recently, Katie Peng sold 1,006 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a transaction totalling $32,725.18. Following the completion of the sale, the director now directly owns 33,914 shares of the company's stock, valued at $1,103,222.42. Learn More on Katie Peng's trading history.
Who are Scholar Rock's active insiders?
Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?
In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company.
Learn More about insider trades at Scholar Rock. Information on this page was last updated on 10/6/2025.
